See more : Xi’an Manareco New Materials Co.,Ltd (688550.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Gujarat Themis Biosyn Limited (GUJTHEM.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gujarat Themis Biosyn Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- The Weir Group PLC (WEGRY) Income Statement Analysis – Financial Results
- Electrameccanica Vehicles Corp. (SOLO) Income Statement Analysis – Financial Results
- Entrée Resources Ltd. (ETG.TO) Income Statement Analysis – Financial Results
- Action S.A. (ACT.WA) Income Statement Analysis – Financial Results
- Sharing Economy International Inc. (SEII) Income Statement Analysis – Financial Results
Gujarat Themis Biosyn Limited (GUJTHEM.BO)
About Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Ltd. operates as a pharmaceutical company. The firm engages in the manufacture of drugs. Its products include Rifamycin and Lovastatin. The company was founded on December 11, 1981 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.70B | 1.49B | 1.14B | 904.25M | 849.77M | 410.50M | 388.00M | 355.87M | 326.25M | 314.40M | 302.30M |
| Cost of Revenue | 687.40M | 307.81M | 208.92M | 211.08M | 154.69M | 318.62M | 316.05M | 290.50M | 263.72M | 7.90M | 173.79M |
| Gross Profit | 1.01B | 1.18B | 933.00M | 693.18M | 695.08M | 91.88M | 71.95M | 65.37M | 62.53M | 306.50M | 128.52M |
| Gross Profit Ratio | 59.52% | 79.34% | 81.70% | 76.66% | 81.80% | 22.38% | 18.54% | 18.37% | 19.17% | 97.49% | 42.51% |
| Research & Development | 38.93M | 29.32M | 4.50M | 0.00 | 0.00 | 304.00K | 280.00K | 0.00 | 0.00 | 0.00 | 149.83K |
| General & Administrative | 13.93M | 14.41M | 8.28M | 6.61M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.26M |
| Selling & Marketing | 3.62M | 10.08M | 2.92M | 1.92M | 5.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.26M |
| SG&A | 17.56M | 37.73M | 11.20M | 8.53M | 9.97M | 11.52M | 15.55M | 14.22M | 12.20M | 41.51M | 50.53M |
| Other Expenses | 100.37M | 60.24M | 713.00K | 1.59M | 1.14M | -17.55M | -2.48M | -1.56M | -1.25M | 0.00 | 0.00 |
| Operating Expenses | 156.85M | 465.50M | 367.25M | 297.68M | 389.78M | 29.38M | 18.31M | 15.79M | 13.45M | 257.56M | 77.93M |
| Cost & Expenses | 844.24M | 773.31M | 576.17M | 508.76M | 544.47M | 347.99M | 334.36M | 306.29M | 277.17M | 265.47M | 251.72M |
| Interest Income | 40.25M | 50.44M | 32.61M | 21.51M | 15.71M | 3.63M | 1.65M | 2.36M | 2.21M | 2.99M | 5.32M |
| Interest Expense | 1.43M | 2.01M | 7.33M | 7.90M | 8.57M | 1.30M | 3.20M | 3.84M | 3.19M | 3.44M | 7.15M |
| Depreciation & Amortization | 40.64M | 25.76M | 22.33M | 17.33M | 13.62M | 12.21M | 11.49M | 11.20M | 11.99M | 13.75M | 14.62M |
| EBITDA | 835.40M | 802.17M | 620.95M | 414.03M | 319.05M | 91.01M | 62.29M | 60.55M | 61.07M | 65.85M | 67.03M |
| EBITDA Ratio | 49.19% | 53.86% | 54.34% | 47.99% | 39.44% | 18.20% | 16.79% | 17.08% | 18.72% | 20.94% | 21.58% |
| Operating Income | 853.98M | 802.41M | 598.21M | 416.66M | 321.49M | 62.51M | 53.64M | 49.59M | 49.08M | 52.09M | 50.60M |
| Operating Income Ratio | 50.29% | 53.86% | 52.39% | 46.08% | 37.83% | 15.23% | 13.83% | 13.93% | 15.04% | 16.57% | 16.74% |
| Total Other Income/Expenses | -60.63M | -12.02M | 18.28M | -254.35M | 7.27M | -254.22M | -5.26M | -243.49M | -227.45M | -219.04M | -5.40M |
| Income Before Tax | 793.34M | 774.65M | 590.35M | 408.82M | 312.57M | 81.96M | 48.38M | 48.85M | 46.29M | 45.94M | 45.26M |
| Income Before Tax Ratio | 46.72% | 52.00% | 51.70% | 45.21% | 36.78% | 19.96% | 12.47% | 13.73% | 14.19% | 14.61% | 14.97% |
| Income Tax Expense | 201.71M | 194.96M | 154.10M | 107.02M | 75.82M | 17.87M | 9.71M | 5.07M | -2.00 | 0.00 | 0.00 |
| Net Income | 591.63M | 579.69M | 436.24M | 301.80M | 236.75M | 64.09M | 38.67M | 43.78M | 46.29M | 45.94M | 45.26M |
| Net Income Ratio | 34.84% | 38.91% | 38.20% | 33.38% | 27.86% | 15.61% | 9.97% | 12.30% | 14.19% | 14.61% | 14.97% |
| EPS | 8.14 | 7.98 | 6.01 | 4.15 | 3.26 | 0.88 | 0.53 | 0.60 | 0.64 | 0.63 | 0.62 |
| EPS Diluted | 5.43 | 7.98 | 6.01 | 4.15 | 3.26 | 0.88 | 0.53 | 0.60 | 0.64 | 0.63 | 0.62 |
| Weighted Avg Shares Out | 72.68M | 72.64M | 72.64M | 72.65M | 72.64M | 72.66M | 72.64M | 72.64M | 72.64M | 72.69M | 72.64M |
| Weighted Avg Shares Out (Dil) | 108.97M | 72.64M | 72.64M | 72.64M | 72.64M | 72.64M | 72.64M | 72.64M | 72.64M | 72.64M | 72.64M |
No news found for: GUJTHEM.BO
Source: https://incomestatements.info
Category: Stock Reports